EAU 2014 - Poster: Cost-utility analysis of onabotulinumtoxinA vs best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Nick Freemantle,1 Kristin Khalaf,2 Daisy Ng-Mak,2,* Clara Loveman,3 Sanja Stanisic,4 Dmitry Gultyaev,5 Johanna Lister,5 and Marcus Drake6 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Poster--Cost-utility EAU thumb

1Department of Primary Care and Population Health, UCL Medical School, London, United Kingdom; 2Allergan Inc., Irvine, CA, USA; 3Allergan Ltd, Marlow, United Kingdom; 4LA-SER ANALYTICA, Milan, Italy; 5LA-SER ANALYTICA, Lörrach, Germany; 6Department of Urology, Southmead Hospital, Bristol, United Kingdom *Currently Sunovion Pharmaceuticals Inc., Marlborough, MA, USA



Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.